Keyhole (VATS) and robotic surgery for lung, mediastinal and food pipe Cancers, planned to protect breathing and speed up recovery.
The chest contains some of the most vital structures in the human body, the lungs, the heart, the oesophagus, the trachea, the great vessels, and the mediastinum with its complex arrangement of lymph nodes, nerves, and glands. When Cancer arises in any of these structures, or when Cancer from elsewhere spreads to the chest, surgical treatment in this anatomical territory requires a specific combination of thoracic surgical expertise and Oncological precision that comes from dedicated surgical Oncology training.
Dr Dinesh Mavinahalli Gangaiah, MS, MCh (Surgical Oncology), is a GI and Thoracic Minimally Invasive and Robotic Surgical Oncologist at ARC Cancer Hospital, Bengaluru. His thoracic Oncology practice covers Cancers of the lung, mediastinum, pleura, chest wall, and oesophagus, delivered through video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracic surgery (RATS), the two most advanced minimally invasive platforms for chest surgery available in India today.
For patients facing a thoracic Cancer diagnosis, the surgical approach matters enormously, not just for Cancer control, but for quality of life during recovery and for preserving respiratory function after surgery. Minimally invasive thoracic surgery allows Dr Dinesh to achieve the same Oncological completeness as open chest surgery (thoracotomy) while sparing patients the prolonged recovery, significant pain, and respiratory complications that large chest incisions historically produced.
Thoracic Cancer surgery is not a procedure that should be performed by any surgeon who has occasionally opened the chest. The anatomical complexity, the proximity to vital structures, and the Oncological demands, complete nodal dissection, margin assessment, reconstruction, require specific training and a high-volume experience in thoracic Oncology.
Dr Dinesh Mavinahalli Gangaiah performs the following thoracic Oncology procedures at ARC Cancer Hospital, Bengaluru, predominantly through VATS (video-assisted thoracoscopic surgery) and robotic-assisted thoracic surgery (RATS):
| Cancer / Condition | Minimally Invasive / Robotic Procedure | Why This Approach |
|---|---|---|
| Lung Cancer(Non-Small Cell: NSCLC) | VATS lobectomy (removal of one lobe of the lung); robotic lobectomy; VATS segmentectomy (anatomical sub-lobar resection, for smaller peripheral tumours); VATS wedge resection (non-anatomical resection for selected cases); systematic mediastinal lymph node dissection (MLND), mandatory for accurate staging | VATS and robotic lobectomy achieve equivalent Oncological outcomes (R0 resection rate, lymph node yield, 5-year survival) compared to open thoracotomy; reduced post-operative pain, shorter chest drain duration, shorter hospital stay (3 to 5 days vs 7 to 10 days), and significantly better preservation of post-operative pulmonary function, critical for patients with pre-existing COPD or reduced lung reserve who constitute the majority of Indian lung Cancer patients |
| Oesophageal Cancer(Cancer of the Food Pipe) | Minimally invasive oesophagectomy (MIO): thoracoscopic chest phase combined with laparoscopic abdominal phase; Ivor Lewis (right thoracoscopic + laparoscopic abdominal + intrathoracic anastomosis) or McKeown (three-field) approach; robotic-assisted oesophagectomy | Oesophageal Cancer surgery is the most demanding cross-domain thoraco-abdominal procedure in surgical Oncology; MIO significantly reduces pulmonary complications and ICU and hospital stay compared to open oesophagectomy |
| Mediastinal Tumours(Thymoma and Thymic Carcinoma) | Thoracoscopic thymectomy (VATS or robotic); complete thymectomy including anterior mediastinal fat for Masaoka stage I, II thymoma; extended resection for advanced thymoma involving adjacent structures | The mediastinum, particularly the anterior mediastinum where the thymus sits, is confined and bounded by the great vessels; robotic thymectomy provides better visualisation and instrument access in this narrow space compared to both open sternotomy and conventional VATS; complete thymectomy (removing the entire thymus and surrounding fat) reduces recurrence risk; also definitive treatment for myasthenia gravis associated with thymoma |
| Mediastinal Tumours(Lymphoma and Germ Cell) | Thoracoscopic biopsy for tissue diagnosis; resection of residual mediastinal mass after chemotherapy in germ cell tumours; video-assisted mediastinoscopy for lymph node staging | Mediastinal lymphoma and mediastinal germ cell tumours are primarily managed with systemic therapy; surgery has a role in tissue diagnosis (VATS biopsy is the standard for anterior mediastinal masses not accessible by needle biopsy) and in resection of post-chemotherapy residual masses in germ cell tumours that may contain mature teratoma |
| Pleural Tumours(Mesothelioma and Pleural Metastases) | Video-assisted thoracoscopic pleurectomy / decortication (VATS P/D); talc pleurodesis under thoracoscopic guidance; pleural biopsy for diagnosis; management of malignant pleural effusion | Pleural mesothelioma and malignant pleural disease require thoracoscopic access for diagnosis (pleural biopsy under direct vision) and for management (pleurodesis, drainage); VATS pleurectomy / decortication is the surgery of choice for selected mesothelioma patients; drainage and pleurodesis for symptomatic malignant pleural effusion improves quality of life in advanced thoracic malignancy |
| Lung Metastases(Secondary Tumours in the Lung) | VATS wedge resection or segmentectomy for pulmonary metastasectomy, resection of secondary deposits from colorectal, sarcoma, renal, or other primary Cancers; single or multiple lesions accessible by VATS | Pulmonary metastasectomy, surgical removal of lung metastases, is indicated in selected patients with limited, resectable pulmonary metastases and controlled primary disease; VATS approach achieves equivalent Oncological outcomes to open thoracotomy for accessible peripheral lesions; significantly shorter recovery allows faster return to systemic therapy where needed |
| Chest Wall Tumours | Chest wall resection: en-bloc resection of primary chest wall tumours (sarcoma, chondrosarcoma, desmoid tumour) or chest wall invasion by lung or breast Cancer; chest wall reconstruction using mesh or synthetic materials | Chest wall resection requires careful preoperative planning for the extent of bony and soft tissue resection and for reconstruction; the goal is complete Oncological resection while maintaining chest wall stability and respiratory function; reviewed at the Multidisciplinary Tumour Board before surgery |
| Tracheal andCarinal Tumours | Tracheal resection and reconstruction for selected primary tracheal tumours; sleeve resection of the carina in selected lung Cancer cases with carinal involvement | Tracheal and carinal surgery is among the most specialised procedures in thoracic Oncology; it requires specific anaesthetic coordination (cross-field ventilation) and surgical expertise in airway reconstruction; cases are reviewed at the Tumour Board with pulmonology, anaesthesiology, and medical Oncology before surgical planning |
Patients and families researching thoracic Cancer surgery frequently encounter three terms, open thoracotomy, VATS, and robotic surgery, without a clear explanation of what each involves and how they differ. Dr Dinesh Mavinahalli Gangaiah performs both VATS and robotic thoracic surgery; open thoracotomy is reserved for cases where minimally invasive access is not Oncologically or technically appropriate. Here is an honest, evidence-based comparison:
| Open Thoracotomy | VATS | Robotic (RATS): Dr Dinesh | |
|---|---|---|---|
| Incision Size | 15 to 30 cm rib-spreading incision | 3 to 4 small ports (1 to 3 cm each) | 3 to 4 robotic ports (1 to 2 cm each) |
| Hospital Stay | 7 to 10 days | 3 to 5 days | 3 to 5 days |
| Post-op Pain | Significant; rib-spreading causes lasting chest wall pain in many patients | Substantially less; no rib spreading | Substantially less; no rib spreading |
| Pulmonary Function Loss | Greater; chest wall disruption affects respiratory mechanics | Significantly less post-op pulmonary function decline | Significantly less; better for patients with reduced lung reserve |
| Lymph Node Dissection | Direct access; technically straightforward | Adequate in experienced hands | Better mediastinal lymph node access and yield, reported in published studies |
| 3D Visualisation | Direct naked eye | HD 2D or 3D camera | 10 to 15× magnified 3D high-definition |
| Instrument Control | Direct manual | Rigid laparoscopic instruments | 7-degree-of-freedom wristed instruments; tremor filtered |
| Return to Activity | 8 to 12 weeks | 3 to 5 weeks | 3 to 5 weeks |
| Oncological Outcomes(Survival, R0 Rate) | Equivalent: the established gold standard | Equivalent to open: confirmed in multiple RCTs | Equivalent to open and VATS: confirmed; better nodal yield in published studies |
| Suited for | Advanced local disease requiring complex reconstruction; cases where MIS is contraindicated | Most standard lung Cancer resections; experienced VATS surgeon essential | Mediastinal dissection; cases requiring better visualisation; narrow spaces (anterior mediastinum); complex hilar anatomy |
The Oncological outcomes, survival, complete resection rate (R0), lymph node yield, are equivalent across all three approaches in experienced hands. The choice between VATS and robotic is determined by tumour location, patient anatomy, and the surgeon’s platform expertise. Open thoracotomy is not the safer option for most patients, it is the more painful option with a longer recovery, equivalent survival, and no Oncological advantage for most resectable thoracic Cancers.
Both VATS and robotic thoracic surgery are minimally invasive, both use small incisions and a camera. The technical differences between them are meaningful in specific clinical contexts:
Lung Cancer is the second most common Cancer in Indian men, and the Cancer with the highest mortality in both sexes globally. In India, the majority of newly diagnosed lung Cancer patients are smokers who also have significant underlying chronic obstructive pulmonary disease (COPD) or reduced lung reserve, a clinical reality that makes the choice of surgical approach more important than it might be in healthier Western patient populations.
Lung Cancer treatment options include surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy. Which of these a patient needs depends on the type and stage of the lung Cancer, the results of tests on the tumour, and the patient’s lung function and general health. For early lung Cancer, surgery is often the main treatment.
No thoracic Cancer surgery at ARC Cancer Hospital is planned without Multidisciplinary Tumour Board review, bringing together thoracic surgical Oncology, medical Oncology, radiation Oncology, pulmonology, and radiology to determine the optimal treatment sequence for each patient.
Your first consultation with Dr Dinesh Mavinahalli Gangaiah reviews all available CT, PET CT, PFT, and bronchoscopy results, along with any biopsy or pathology already obtained. The discussion covers your diagnosis and stage, whether surgery is recommended and at what point in your treatment, which surgical approach is planned and why, and what recovery involves. You are encouraged to bring a family member and to write down any questions before the appointment.
Dr Dinesh Mavinahalli Gangaiah practises at ARC Cancer Hospital, Bengaluru, Dr MH Marigowda Road, Lakkasandra, Hombegowda Nagar, Bengaluru, 560027. He consults patients from across Bengaluru and Karnataka, and from Tamil Nadu, Andhra Pradesh, Telangana, and Kerala for minimally invasive and robotic thoracic Oncology surgery.
VATS, Video-Assisted Thoracoscopic Surgery, is a minimally invasive approach to chest surgery performed through 3 to 4 small incisions (1 to 3 cm each) using a thoracoscope (a thin camera) and long-handled instruments. Unlike open thoracotomy, which requires a 15 to 30 cm incision and spreading of the ribs, VATS avoids rib spreading entirely, significantly reducing post-operative pain, blood loss, chest drain duration, and hospital stay. Multiple large randomised controlled trials and systematic reviews have confirmed that VATS lobectomy for lung Cancer achieves equivalent Oncological outcomes to open thoracotomy, the same complete resection (R0) rate, the same lymph node yield, and the same long-term survival, while reducing the patient experience burden. VATS lung Cancer surgery is not an experimental technique. It is the international standard of care for resectable lung Cancer at experienced centres, and has been for over a decade.
Both VATS and robotic surgery are minimally invasive thoracic approaches, both use small ports and a camera, avoiding large chest incisions. The difference is in the instruments and visualisation. VATS uses rigid long-handled instruments controlled directly by the surgeon, with a high-definition camera view on a monitor. Robotic surgery uses a surgical console at which the surgeon sits and controls flexible robotic instruments with seven degrees of freedom, instruments that replicate the movement of the human wrist inside the chest, with 10 to 15 times magnified 3D high-definition visualisation. Published studies suggest that robotic-assisted thoracic surgery achieves better mediastinal lymph node dissection than uniportal VATS, an important Oncological advantage, because thorough nodal dissection determines whether adjuvant therapy is needed after lung resection. For mediastinal tumours (thymoma), oesophageal Cancer surgery, and complex hilar dissection, robotic assistance provides meaningful additional precision. For many standard peripheral lung resections, both approaches achieve equivalent outcomes.
For Stage I and selected Stage II non-small cell lung Cancer (NSCLC), Cancer confined to the lung without lymph node involvement or distant metastasis, surgical resection is the primary curative treatment. Lobectomy (removal of the affected lobe of the lung) with systematic mediastinal lymph node dissection is the standard of care for most resectable early-stage lung Cancers. Segmentectomy (anatomical sub-lobar resection) is an acceptable alternative for tumours smaller than 2 cm with favourable characteristics. At ARC Cancer Hospital, the decision between lobectomy and segmentectomy, and the choice of surgical approach (VATS vs robotic vs open), is reviewed at the Multidisciplinary Tumour Board with pulmonology, medical Oncology, and radiation Oncology input. For patients who are not suitable for surgery due to reduced lung function or comorbidities, stereotactic body radiation therapy (SBRT) is an alternative that Dr Dinesh co-ordinates with the radiation Oncology team at ARC Cancer Hospital.
Reduced lung function, common in Indian lung Cancer patients with a long smoking history, does not automatically exclude surgery. The key assessment is whether your predicted post-operative lung function (after removing the planned lobe) will be adequate to support normal breathing and daily activity. This is calculated from your pre-operative spirometry and DLCO results, combined with a ventilation-perfusion scan where needed. VATS and robotic lobectomy preserve significantly more post-operative pulmonary function than open thoracotomy, because avoiding rib spreading preserves the chest wall mechanics that drive breathing. Many patients who would be borderline or excluded candidates for open thoracotomy are safe and appropriate candidates for minimally invasive lobectomy. Dr Dinesh assesses every patient’s respiratory reserve carefully before surgical planning, working with ARC Cancer Hospital’ pulmonology team where needed.
The thymus is a small gland in the front of the chest (anterior mediastinum) that plays a role in immune system development in childhood. Thymoma is a tumour arising from the thymus, the most common primary tumour of the anterior mediastinum. Most thymomas are slow-growing and localised, and complete surgical resection (thymectomy, removal of the entire thymus and surrounding mediastinal fat) is curative for most Stage I and Stage II thymomas. Thymoma is also associated with myasthenia gravis, a neuromuscular condition in which thymectomy improves or resolves the condition in a significant proportion of patients. Dr Dinesh performs robotic thymectomy at ARC Cancer Hospital, a minimally invasive approach that provides better visualisation of the anterior mediastinum and avoids the sternotomy (breastbone incision) required for open thymectomy, with significantly faster recovery.
After VATS or robotic lobectomy for lung Cancer, most patients follow this recovery timeline: Day 1 after surgery, sitting up, breathing exercises, walking in the corridor with physiotherapy support; Days 2 to 3, chest drains removed when air and fluid output is minimal; Day 3 to 5, discharge from hospital (the majority of patients go home within 3 to 5 days after VATS lobectomy); Weeks 1 to 2, light activity at home; walking increasing daily; no heavy lifting; Week 3 to 4, return to driving; most office-based work resumed; Week 4 to 6, return to full normal activity for most patients. Pulmonary rehabilitation, structured breathing exercises and a graded walking programme, is coordinated by ARC Cancer Hospital’ physiotherapy team and significantly accelerates recovery and restoration of lung function after thoracic surgery.
Yes. VATS lobectomy, robotic lobectomy, minimally invasive oesophagectomy, thymectomy, pleurectomy, and other thoracic Oncology procedures are covered under most major health insurance providers and under Ayushman Bharat / PMJAY for eligible patients at ARC Cancer Hospital. Our patient services team provides pre-authorisation support. Please contact us at +91 99160 99360 or use the appointment booking system to discuss your coverage before scheduling surgery.
Most people can return to their normal daily activities. Before surgery, breathing tests check how much lung can be safely removed, and the operation is planned around that result. You may feel short of breath on exertion for some weeks; breathing exercises and walking help, and this usually improves over time.
This website gives general information about Cancer and Cancer surgery. It is not medical advice for your situation and does not replace a consultation with a qualified doctor.
Copyright© 2026 Dr Dinesh Mavinahalli Gangaiah. Privacy Policy · Terms & Conditions
